Menu

News

September 26, 2024

Freight of small vesicles offers new treatment approach for pulmonary fibrosis

A healthy lung can recover from small injuries caused by viruses or pollutants. However, this regenerative ability is impaired in patients with pulmonary fibrosis.
Read more
August 28, 2024

New study confirms the predictive power of risk models across different groups of pulmonary hypertension

A recent study published in the scientific journal CHEST, led by DZL scientists from the Institute for Lung Health (ILH) in Gießen, investigated the effectiveness of various risk models for predicting different forms of Pulmonary Hypertension (PH).
Read more
August 21, 2024

Lung cancer: An official research statement from the American Thoracic Society

Lung cancer remains the leading cause of cancer-related deaths in the U.S. and Europe. Despite available treatments, more than 70% of patients experience relapse and eventually succumb to the disease, often due to its spread to other parts of the body.
Read more
August 5, 2024

New Hope for PAH: Seralutinib Shows Promising Results

Pulmonary arterial hypertension (PAH) is a rare but serious condition characterized by high blood pressure in the arteries that connect the heart to the lungs. This disease leads to the narrowing and thickening of the arterial walls, which impairs blood flow and increases the pressure in the pulmonary arteries.
Read more
August 2, 2024

Immunotherapy in Lung Cancer: Rajkumar Savai on Challenges and Advances

Lung cancer is the leading cause of cancer deaths worldwide. While early-stage lung cancer can often be treated with radical surgical interventions or chemotherapy, over 70% of patients experience recurrences, primarily due to the spread of the cancer to other parts of the body.
Read more
July 24, 2024

Eosinophil count as a biomarker for the severity of pneumonia

A team of researchers at the University of Marburg has discovered a potential biomarker for predicting the course of disease in community-acquired pneumonia.
Read more
July 23, 2024

Scientific Breakthrough in COPD Treatment: Dupilumab Shows Significant Benefits

Dupilumab reduces the number of severe exacerbations and improves lung function in COPD patients with type 2 inflammation, according to a study involving DZL scientists.
Read more
July 11, 2024

Cystic fibrosis: School-aged children benefit from triple combination therapy

Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time.
Read more
July 9, 2024

Wenn das „rechte“ Herz versagt: Entschlüsselung von genetischen Netzwerken der fortschreitenden Rechtsherzschwäche

Arbeitsgruppen aus der Pharmakologie und der Physiologie der Justus-Liebig-Universität Gießen (JLU) veröffentlichen Studie zur Rechtsherzinsuffizienz.
Read more
July 4, 2024

Artificial Ventilation Can Create Germ Centers for Acute Respiratory Distress Syndrome

Artificial ventilation can save lives but also strains lung tissue. If the lungs are already damaged, pressure ventilation can have undesirable effects. This primarily affects patients with Acute Respiratory Distress Syndrome (ARDS).
Read more
June 28, 2024

National Strategy for Gene and Cell Therapies opens up new perspectives for patients

In fall 2022, the Federal Ministry of Education and Research (BMBF) commissioned the Berlin Institute of Health at Charité (BIH) to coordinate the creation of a national strategy for gene- and cell-based therapies.
Read more
June 10, 2024

Enormous Engagement at the 12th DZL Annual Meeting in Bad Nauheim

From June 5 to 7, 2024, the 12th Annual Meeting of the German Center for Lung Research (DZL) took place at the UGMLC site in Bad Nauheim. The event impressed with a record-breaking attendance of 630 participants and showcased the largest Poster Session in DZL history.
Read more
May 31, 2024

Focus on new therapies for pulmonary hypertension

New therapies for pulmonary hypertension (PH) are the focus of the Giessen Collaborative Research Centre (CRC) 1213. Around 100 million people worldwide are affected by various forms of PH.
Read more
May 29, 2024

Werner Seeger receives prestigious Lifetime Achievement Award at ATS congress

At this year's American Thoracic Society (ATS) congress in San Diego, Prof Werner Seeger, Chairman of the Board and Spokesman of the DZL, received the prestigious Robert F. Grover Award for his life's work in the field of pulmonary hypertension (PH) research.
Read more
May 27, 2024

Innate mechanism protects bacteria from last-resort antibiotic

Last-resort antibiotics such as polymyxin are used for bacterial infections when conventional antibiotics fail. However, new research findings show that bacteria have an innate mechanism that protects them from polymyxin.
Read more
May 3, 2024

How obesity and pulmonary fibrosis are linked

DZL scientists Prof Mareike Lehmann and Prof Miguel Alejandre-Alcazar from Justus Liebig University Giessen have received over half a million euros from the German Research Foundation (DFG) to investigate the link between obesity and lung ageing.
Read more
April 5, 2024

Rapid action against climate change protects against immune-mediated diseases

Climate change, environmental pollution and the decline in biodiversity affect our immune system and increase the risk of immune-mediated diseases such as asthma and allergies.
Read more
March 27, 2024

DGP Research Award 2024: DZL Researcher Discovers Endogenous Molecule Impacting COPD Defense

The identification of a new molecule has the potential to open new avenues in the diagnosis and treatment of Chronic Obstructive Pulmonary Disease (COPD).
Read more
February 27, 2024

DZG for an open and democratic society

The wave of protests against right-wing extremism with demonstrations in many places in Germany has been ongoing for about a month. The trigger was revelations by the investigative center Correctiv about a meeting of radical right-wingers in November.
Read more
February 8, 2024

One million euros for cutting-edge medical research

Life-threatening heart and lung diseases, antibiotic resistance in hospital-acquired pathogens, Parkinson's, and coronaviruses - these are the medical challenges that the current research projects of the Von Behring-Röntgen Foundation are addressing.
Read more
1 2 3
More news can be found on the DZL news site. The link below leads to a pre-filtered overview of all UGMLC-related news.  
To DZL news area
chevron-down